Drug: Cymbalta  
Company: Eli Lilly
Total spend Q1, 2012: $46.7 million
Total spend Q1, 2011: $440,360
Watch the TV commerical here >>

Clearly, Eli Lilly ($LLY) is milking this cow for all it is worth before its patent expires. That would have happened at the end of June 2013, but the FDA extended the patent for another 6 months through its pediatric-exclusivity program after Lilly studied the effects of the antidepressant on children and adolescents. Cymbalta is Lilly's second best-selling drug, generating $3.2 billion last year behind another antidepressant, Zyprexa. In the first quarter, when this ad spend was happening, the drug brought in more than $1 billion in retail sales, says, up 7.6%, after Lilly boosted its price.


Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.